Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | LDHA | P00338 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | CTBP2 | P56545 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | ATM | Q13315 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | KLK7 | P49862 | 1/20 | 0.46 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.46 |
| ▸ | CNR2 | P34972 | 1/20 | 0.46 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10196972 | 0.87 | HTT (0.51) | HTTSMN1; SMN2LDHALMNACTBP2 | |
| SCHEMBL18827710 | 0.87 | HTT (0.51) | HTTSMN1; SMN2LDHALMNACTBP2 | |
| SCHEMBL559690 | 0.84 | ALDH1A1 (0.44) | SMN1; SMN2LMNAKMT2AATMTDP1 | |
| SCHEMBL10050755 | 0.82 | CA2 (0.48) | LMNACTBP2KMT2A | |
| SCHEMBL558881 | 0.82 | KMT2A (0.47) | HTTSMN1; SMN2LMNACTBP2L3MBTL1 | |
| SCHEMBL10051142 | 0.82 | SMN1; SMN2 (0.59) | SMN1; SMN2LMNAALDH1A1KDM4E | |
| SCHEMBL560140 | 0.81 | CTBP2 (0.54) | HTTSMN1; SMN2CTBP2KMT2AALDH1A1 | |
| SCHEMBL560131 | 0.81 | PPARA (0.38) | CYP3A4POLB | |
| SCHEMBL16144858 | 0.81 | TDP1 (0.51) | HTTSMN1; SMN2LMNACTBP2KMT2A | |
| SCHEMBL934793 | 0.80 | TSHR (0.50) | SMN1; SMN2LMNAL3MBTL1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9645128-B2 | Substituted imidazo[1,2-A]pyrazines for measuring a transcription activity | JNC CORPORATION (JP) | 2017-05-09 | — | — | US | disclosed |
| US-9645128-B2 | Substituted imidazo[1,2-A]pyrazines for measuring a transcription activity | JNC CORPORATION (JP) | 2017-05-09 | — | — | US | disclosed |
| US-20150344936-A1 | COELENTERAZINE ANALOGS AND MANUFACTURING METHOD THEREOF | TOKYO INSTITUTE OF TECHNOLOGY (JP) | 2015-12-03 | — | — | US | disclosed |
| US-20150344936-A1 | COELENTERAZINE ANALOGS AND MANUFACTURING METHOD THEREOF | TOKYO INSTITUTE OF TECHNOLOGY (JP) | 2015-12-03 | — | — | US | disclosed |
| US-9151739-B2 | Coelenterazine analogs and manufacturing method thereof | JNC CORPORATION (JP) | 2015-10-06 | — | — | US | disclosed |
| US-9151739-B2 | Coelenterazine analogs and manufacturing method thereof | JNC CORPORATION (JP) | 2015-10-06 | — | — | US | disclosed |
| US-20140296521-A1 | COELENTERAZINE ANALOGS AND MANUFACTURING METHOD THEREOF | JNC CORP (JP) | 2014-10-02 | — | — | US | disclosed |
| US-20140296521-A1 | COELENTERAZINE ANALOGS AND MANUFACTURING METHOD THEREOF | JNC CORP (JP) | 2014-10-02 | — | — | US | disclosed |
| US-8765921-B2 | Coelenterazine analogs and manufacturing method thereof | JNC CORPORATION (JP) | 2014-07-01 | — | — | US | disclosed |
| US-8765921-B2 | Coelenterazine analogs and manufacturing method thereof | JNC CORPORATION (JP) | 2014-07-01 | — | — | US | disclosed |
| US-20140024058-A1 | COELENTERAZINE ANALOGS AND MANUFACTURING METHOD THEREOF | TOKYO INSTITUTE OF TECHNOLOGY (JP) | 2014-01-23 | — | — | US | disclosed |
| US-20140024058-A1 | COELENTERAZINE ANALOGS AND MANUFACTURING METHOD THEREOF | TOKYO INSTITUTE OF TECHNOLOGY (JP) | 2014-01-23 | — | — | US | disclosed |
| US-8546568-B2 | Coelenterazine analogs and manufacturing method thereof | JNC CORPORATION (JP) | 2013-10-01 | — | — | US | disclosed |
| US-8546568-B2 | Coelenterazine analogs and manufacturing method thereof | JNC CORPORATION (JP) | 2013-10-01 | — | — | US | disclosed |
| US-20120035070-A1 | COELENTERAZINE ANALOGS AND MANUFACTURING METHOD THEREOF | TOKYO INSTITUTE OF TECHNOLOGY (JP) | 2012-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140296521-A1 | COELENTERAZINE ANALOGS AND MANUFACTURING METHOD THEREOF | GLB1, CEL, SI | HTT 2943/4885SMN1; SMN2 4175/4885LDHA 3841/4885 |
| US-20120035070-A1 | COELENTERAZINE ANALOGS AND MANUFACTURING METHOD THEREOF | GLB1, CEL, SI | HTT 2943/4885SMN1; SMN2 4175/4885LDHA 3841/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.